Finzati - Logo
GRFS logo

Grifols, S.A.

GRFS • Drug Manufacturers - General
$7.54
— 0.00 (0.00%)
EarningsLatest report: Mar 31, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Solid company profile with reasonable valuation support. The data suggests a balanced quality/value setup.
Market Cap
$5.13B
Growth
11.3%
Cash Flow
3/5
Trend
Mostly stable
Evidence
Stable or improving margins · 5.3%Positive revenue growth · 10.1%Positive free cash flow · 1.1Reasonable earnings multiple · 14.03Healthy liquidity · 2.51
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 7, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$7.54
Change0.00%
Shares Out680.58M
Market Cap$5.13B
52W Range7.25 - 11.14
Beta1.17
P/E16.48
P/S2.83
P/B0.90
P/FCF82.96
EV/Sales7.93
EV/EBITDA38.18

Investment DNA

How strong this company looks for long-term investors

75
out of 100
Business Quality
Margins, moat, returns
63/100
Financial Strength
Debt, cash, stability
51/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
91/100
Why this score▼
Stable or improving margins · 5.3%Positive revenue growth · 10.1%Positive free cash flow · 1.1Reasonable earnings multiple · 14.03Healthy liquidity · 2.51

Analyst view

Analyst sentiment and price target

GRFS
Analyst sentiment
Based on 8 analyst votes · 2026-10-20
63/100
Neutral
Bullish
4
Hold
2
Bearish
2

Company Overview

IPO: 6/2/2011
Industry: Drug Manufacturers - General
P/B i: 0.90
Debt / Equity i: 1.66
Operating Margin: 16.43%
Net Margin: 5.34%
ROE i: -
ROIC: -

Financial Health

Score10 / 20
Debt / Equity: 1.66
Current Ratio: 2.51
Quick Ratio: 0.88
Status: Moderate
🧾

No insider activity

No recent insider transactions available.